Contineum Therapeutics, Inc. filing reports that Balyasny Asset Management and affiliated entities may be deemed to beneficially own 2,417,723 shares of Class A common stock, representing approximately 7.40% of the class. The shares are held directly by Atlas Diversified Master Fund, Ltd. and the filing attributes voting and investment power to BAM and related reporting persons based on their managerial roles. The 7.40% calculation is based on 32,673,536 Shares outstanding as of February 27, 2026 per the issuer's 10-K.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed: 2,417,723 shares (7.40%) held via ADMF.
Balyasny Asset Management and affiliated entities report beneficial ownership of 2,417,723 shares of Class A common stock through Atlas Diversified Master Fund, Ltd. The filing attributes voting and investment power to BAM and its chain of affiliates and principals by virtue of management roles.
The excerpt states that ADMF is the direct holder and has the right to receive dividends or sale proceeds. Subsequent public filings or fund schedules would show whether these shares are intended as a long‑term holding or available for trading.
Schedule 13G used to report passive/beneficial ownership with manager attribution.
The statement shows BAM, BAM GP, BAM Holdings, Dames, and Dmitry Balyasny as reporting persons and explains the chain of control that leads to beneficial ownership attribution of 2,417,723 shares. The filing cites the issuer's 10-K share count as of February 27, 2026.
Filing signatures include an authorized signatory and Mr. Balyasny. The excerpt identifies the direct holder (ADMF) as the entity entitled to dividends or sale proceeds.
Key Figures
Reported shares:2,417,723 sharesPercent of class:7.40%Shares outstanding used:32,673,536 Shares
3 metrics
Reported shares2,417,723 sharesheld directly by ADMF; beneficially owned by BAM entities
Percent of class7.40%based on 32,673,536 Shares outstanding as of February 27, 2026
Shares outstanding used32,673,536 Sharesas of February 27, 2026 per issuer's 10-K
Key Terms
Beneficially own, Schedule 13G, Direct holder
3 terms
Beneficially ownregulatory
"By virtue of its position as the investment manager of Atlas Diversified Master Fund, Ltd."
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Schedule 13Gregulatory
"This statement is being filed by (1) Balyasny Asset Management L.P."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Direct holdermarket
"ADMF, the direct holder of the 2,417,723 shares of Class A common stock"
What stake does Balyasny report in Contineum Therapeutics (CTNM)?
They report beneficial ownership of 2,417,723 shares, representing approximately 7.40% of Class A common stock based on 32,673,536 shares outstanding as of February 27, 2026. The shares are held by ADMF.
Who directly holds the 2,417,723 shares reported in the 13G?
The filing states that Atlas Diversified Master Fund, Ltd. (ADMF) is the direct holder of the reported 2,417,723 shares, with Balyasny entities reporting beneficial ownership through managerial roles.
How is voting and investment power attributed in this filing?
The filing explains attribution by roles: BAM is ADMF's investment manager, BAM GP is BAM's general partner, BAM Holdings is sole member of BAM GP, Dames is general partner of BAM Holdings, and Mr. Balyasny is Managing Member of Dames.
Does ADMF retain rights to dividends or sale proceeds for these shares?
Yes. The filing states that ADMF has the right to receive dividends from, or the proceeds from the sale of, the reported securities held by ADMF.
What share count does the filing use to calculate the 7.40% figure?
The percentage is based on 32,673,536 Shares outstanding as of February 27, 2026, as reported in the issuer's Form 10-K referenced in the filing.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Contineum Therapeutics, Inc.
(Name of Issuer)
Class A Common Stock, par value $0.001 per share
(Title of Class of Securities)
21217B100
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
21217B100
1
Names of Reporting Persons
Balyasny Asset Management L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,417,723.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,417,723.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,417,723.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.40 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
21217B100
1
Names of Reporting Persons
BAM GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,417,723.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,417,723.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,417,723.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.40 %
12
Type of Reporting Person (See Instructions)
HC, OO
SCHEDULE 13G
CUSIP Number(s):
21217B100
1
Names of Reporting Persons
Balyasny Asset Management Holdings LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,417,723.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,417,723.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,417,723.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.40 %
12
Type of Reporting Person (See Instructions)
HC, PN
SCHEDULE 13G
CUSIP Number(s):
21217B100
1
Names of Reporting Persons
Dames GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,417,723.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,417,723.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,417,723.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.40 %
12
Type of Reporting Person (See Instructions)
HC, OO
SCHEDULE 13G
CUSIP Number(s):
21217B100
1
Names of Reporting Persons
Dmitry Balyasny
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,417,723.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,417,723.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,417,723.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.40 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Contineum Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
3565 General Atomics Court, Suite 200, San Diego, CA, 92121
Item 2.
(a)
Name of person filing:
This statement is being filed by (1) Balyasny Asset Management L.P., a Delaware limited partnership ("BAM"), (2) BAM GP LLC, a Delaware limited liability company ("BAM GP"), (3) Balyasny Asset Management Holdings LP, a Delaware limited partnership ("BAM Holdings"), (4) Dames GP LLC, a Delaware limited liability company ("Dames"), and (5) Dmitry Balyasny, a United States citizen (collectively, the "Reporting Persons"). BAM GP is the General Partner of BAM. BAM Holdings is the Sole Member of BAM GP. Dames is the General Partner of BAM Holdings. Dmitry Balyasny is the Managing Member of Dames.
(b)
Address or principal business office or, if none, residence:
The principal business address of each of BAM, BAM GP, BAM Holdings, Dames, and Mr. Balyasny is located at 444 West Lake Street, 50th Floor, Chicago, IL 60606.
(c)
Citizenship:
(1) BAM is a Delaware limited partnership, (2) BAM GP is a Delaware limited liability company, (3) BAM Holdings is a Delaware limited partnership, (4) Dames is a Delaware limited liability company, and (5) Mr. Balyasny is a United States citizen.
(d)
Title of class of securities:
Class A Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
21217B100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
By virtue of its position as the investment manager of Atlas Diversified Master Fund, Ltd. ("ADMF"), the direct holder of the 2,417,723 shares of Class A common stock, par value $0.001 per share ("Shares"), reported herein, BAM may be deemed to exercise voting and investment power over such Shares held by ADMF and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM, BAM GP may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares. By virtue of its position as the Sole Member of BAM GP, BAM Holdings may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM Holdings, Dames may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares. By virtue of his position as the Managing Member of Dames, Mr. Balyasny may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares.
(b)
Percent of class:
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 7.40% of the Shares, based on 32,673,536 Shares of Class A common stock outstanding as of February 27, 2026 as reported in the Issuer's 10-K filed with the Securities and Exchange Commission on March 5, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Each of the Reporting Persons has the sole power to vote or to direct the vote of 2,417,723 shares.
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
Each of the Reporting Persons has the sole power to vote or to direct the vote of 2,417,723 shares.
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
ADMF, a Cayman Islands exempted company that is an investment management client of BAM, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
